Aldeyra Therapeutics (ALDX) Non-Current Debt (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Non-Current Debt for 14 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 0.65% year-over-year to $15.0 million; the trailing twelve-month figure through Mar 2026 stood at $15.0 million (down 0.65% YoY), and the FY2025 full-year result was $15.0 million, changed 0.0% from the prior year.
• Non-Current Debt steadied at $15.0 million in Q1 2026 per ALDX's latest filing, from $15.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $15.6 million in Q1 2022 and bottomed at $15.0 million in Q2 2022.
• Historically, Non-Current Debt has averaged $15.0 million across 5 years, with a median of $15.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Non-Current Debt advanced 3.91% in 2022, then retreated 3.76% in 2023.
• Over 5 years, Non-Current Debt stood at $15.0 million in 2022, then changed by 0.0% to $15.0 million in 2023, then changed by 0.0% to $15.0 million in 2024, then changed by 0.0% to $15.0 million in 2025, then changed by 0.0% to $15.0 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $15.0 million, $15.0 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.